{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"To determine the feasibility of multimodal lung sparing regimen. Intrapleural chemotherapy (12 weeks) will be administered within two weeks after surgery. Approximately 30 days post last dose of chemotherapy (+/- 14 days), the patient should be reassessed for resolution of any treatment-related toxicity which may have occurred during the course of study participation.","groups":[{"description":"Intrapleural chemotherapy plus systemic chemotherapy:\n\nThoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy.\n\nDoxorubicin: A medication used in cancer chemotherapy, derived by chemical semisynthesis from a bacterial species.\n\nCisplatin: Platinum-based antineoplastic\n\nPemetrexed: Folate Analog Metabolic Inhibitor\n\nRadiotherapy: Standard procedure given 3 weeks after last dose of chemotherapy","id":"OG000","title":"Multimodal Lung Sparing Regimen"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"20 weeks","title":"Number of Subjects Who Were Able to Complete Trimodal Therapy (Combination of Surgery, Intrapleural and Systemic Chemotherapy and P-32 Radiotherapy).","type":"PRIMARY","unitOfMeasure":"Participants"}